Lupin Limited, a leading global pharmaceutical company, has announced that it received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its Pithampur Unit-1 manufacturing facility. This facility handles the production of both active pharmaceutical ingredients (APIs) and finished pharmaceutical products.
The EIR follows an inspection conducted by the US FDA from September 16 to September 27, 2024, and classifies the facility under "Voluntary Action Indicated" (VAI).
Commenting on the development, Nilesh Gupta, Managing Director of Lupin, said, "We are pleased to receive the EIR from the US FDA for our Pithampur Unit-1 facility with a satisfactory VAI classification. This reflects our commitment to the highest standards of quality and compliance."
